CA3008621A1 - Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk - Google Patents

Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk Download PDF

Info

Publication number
CA3008621A1
CA3008621A1 CA3008621A CA3008621A CA3008621A1 CA 3008621 A1 CA3008621 A1 CA 3008621A1 CA 3008621 A CA3008621 A CA 3008621A CA 3008621 A CA3008621 A CA 3008621A CA 3008621 A1 CA3008621 A1 CA 3008621A1
Authority
CA
Canada
Prior art keywords
hmwk
peptide
seq
sample
plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3008621A
Other languages
English (en)
French (fr)
Inventor
Jiang Wu
Guodong Zhang
Daniel J. Sexton
Ryan Faucette
Gul M. Mustafa
Mark SZEWC
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of CA3008621A1 publication Critical patent/CA3008621A1/en
Pending legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/62Detectors specially adapted therefor
    • G01N30/72Mass spectrometers
    • G01N30/7233Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/88Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848Methods of protein analysis involving mass spectrometry
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N2030/022Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027Liquid chromatography
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/88Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00Chemical aspects of mass spectrometric analysis of biological material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/22Haematology
    • G01N2800/224Haemostasis or coagulation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Enzymes And Modification Thereof (AREA)
CA3008621A 2015-12-15 2016-12-15 Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk Pending CA3008621A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562267734P 2015-12-15 2015-12-15
US62/267,734 2015-12-15
PCT/US2016/066936 WO2017106504A1 (en) 2015-12-15 2016-12-15 Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk

Publications (1)

Publication Number Publication Date
CA3008621A1 true CA3008621A1 (en) 2017-06-22

Family

ID=57794352

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3008621A Pending CA3008621A1 (en) 2015-12-15 2016-12-15 Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk

Country Status (13)

Country Link
US (3) US11668718B2 (cg-RX-API-DMAC7.html)
EP (2) EP4597115A3 (cg-RX-API-DMAC7.html)
JP (3) JP7092669B2 (cg-RX-API-DMAC7.html)
KR (2) KR102874711B1 (cg-RX-API-DMAC7.html)
CN (1) CN108602877A (cg-RX-API-DMAC7.html)
AU (3) AU2016372159B2 (cg-RX-API-DMAC7.html)
CA (1) CA3008621A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018007216A2 (cg-RX-API-DMAC7.html)
EA (1) EA201891414A1 (cg-RX-API-DMAC7.html)
IL (4) IL312919B1 (cg-RX-API-DMAC7.html)
MX (2) MX2018007493A (cg-RX-API-DMAC7.html)
NZ (1) NZ743482A (cg-RX-API-DMAC7.html)
WO (1) WO2017106504A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3060582B1 (en) 2013-10-21 2020-09-23 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
US10101344B2 (en) 2013-10-21 2018-10-16 Dyax Corp. Diagnosis and treatment of autoimmune diseases
DK3365685T3 (da) 2015-10-19 2021-03-01 Dyax Corp Immunoassay til påvisning af spaltet højmolekylært kininogen
EP4597115A3 (en) 2015-12-15 2025-08-13 Takeda Pharmaceutical Company Limited Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk
EP3637106B1 (en) * 2017-06-08 2023-03-22 University of Miyazaki Lung cancer detection method

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047323A (en) * 1986-01-22 1991-09-10 Temple University Of The Commonwealth System Of Higher Education Method for detecting human kininogen using monoclonal antibodies thereto
JP2603487B2 (ja) 1987-11-26 1997-04-23 大日本製薬株式会社 ガンに罹患している疑いのあるヒトをスクリーニングする方法
JPH08208692A (ja) 1994-09-28 1996-08-13 Sumitomo Pharmaceut Co Ltd 新規な細胞接着抑制ペプチド誘導体
JP3073439B2 (ja) * 1996-02-08 2000-08-07 雪印乳業株式会社 骨形成促進及び骨吸収防止剤
WO2000027415A2 (en) 1998-11-10 2000-05-18 Temple University - Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by peptide analogs of high molecular weight kininogen domain 5
US20060154319A1 (en) 1999-04-29 2006-07-13 Flodgaard Hans J Inhibition of bradykinin release
AU1761601A (en) 1999-11-12 2001-06-06 Bristol-Myers Squibb Pharma Company Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain
JP2006501139A (ja) 2002-03-15 2006-01-12 アテニュオン, エルエルシー 血管形成阻害の標的としての細胞表面トロポミオシン
CN1858243A (zh) 2005-04-30 2006-11-08 安徽省生物医学研究所 一种预测血管紧张素ii受体拮抗剂类降压药药物作用的方法及其应用
WO2009051259A1 (ja) 2007-10-18 2009-04-23 Miyazaki Prefectural Industrial Support Foundation 肝疾患診断用バイオマーカー
US20110160434A1 (en) 2008-07-07 2011-06-30 Nippon Zoki Pharmaceutical Co., Ltd. Fibromyalgia test method
GB0821721D0 (en) 2008-11-27 2008-12-31 Hansa Medical Ab Antimicrobial therapy
DK3173792T3 (da) 2009-03-30 2019-08-05 Novartis Ag Crp neo-epitop fibrose-assay
JP5714285B2 (ja) 2010-09-29 2015-05-07 株式会社プロトセラ 妊娠高血圧症候群マーカーおよびそれを用いた診断
CN102558329A (zh) 2010-12-10 2012-07-11 中国人民解放军军事医学科学院生物医学分析中心 一组特异性多肽及其在制备肺癌早期诊断试剂中的用途
PL2831113T3 (pl) 2012-03-28 2018-08-31 Sanofi Przeciwciała przeciwko ligandom receptora bradykininy B1
SMT201800563T1 (it) * 2013-01-20 2018-11-09 Dyax Corp Valutazione e trattamento di disturbi mediati da bradichinina
JP2016188761A (ja) 2013-08-23 2016-11-04 国立研究開発法人国立国際医療研究センター 糖尿病腎症の発症または発症リスクの検出方法及びキット
EP3060582B1 (en) * 2013-10-21 2020-09-23 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
US10281473B2 (en) * 2014-02-04 2019-05-07 University Of Virginia Patent Foundation Compositions and methods for analysis of protein sequences and post-translational modifications
CN104345154B (zh) 2014-08-22 2016-10-26 北京蛋白质组研究中心 一种检测多肿瘤相关“多肽-蛋白组合式标志物”的双抗体夹心试剂盒
CN104155457B (zh) 2014-08-22 2016-11-16 北京蛋白质组研究中心 一种结直肠癌相关“多肽-蛋白组合式标志物”检测试剂盒
US10295550B2 (en) * 2014-11-17 2019-05-21 The Rockefeller University Compositions and methods for use in diagnosis of alzheimer's disease
EP4597115A3 (en) 2015-12-15 2025-08-13 Takeda Pharmaceutical Company Limited Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk

Also Published As

Publication number Publication date
US12135329B2 (en) 2024-11-05
IL259995B2 (en) 2023-05-01
US20230408528A1 (en) 2023-12-21
AU2022204058B2 (en) 2024-10-31
IL312919A (en) 2024-07-01
IL312919B1 (en) 2025-10-01
IL297850B2 (en) 2024-10-01
JP2019505185A (ja) 2019-02-28
US20210025898A1 (en) 2021-01-28
US20250172567A1 (en) 2025-05-29
KR20180134838A (ko) 2018-12-19
WO2017106504A8 (en) 2017-07-13
MX2018007493A (es) 2018-09-18
NZ743482A (en) 2023-04-28
EA201891414A1 (ru) 2019-02-28
IL322971A (en) 2025-10-01
IL297850B1 (en) 2024-06-01
AU2022204058A1 (en) 2022-06-30
IL259995A (en) 2018-07-31
EP4597115A2 (en) 2025-08-06
CO2018007216A2 (es) 2018-09-20
EP3390439A1 (en) 2018-10-24
AU2016372159B2 (en) 2022-03-24
KR20240161708A (ko) 2024-11-12
KR102874711B1 (ko) 2025-10-23
IL297850A (en) 2023-01-01
KR102728491B1 (ko) 2024-11-13
WO2017106504A1 (en) 2017-06-22
AU2025200412A1 (en) 2025-02-13
BR112018012165A2 (pt) 2018-12-04
EP3390439B1 (en) 2025-03-12
AU2016372159A1 (en) 2018-07-05
JP2022141640A (ja) 2022-09-29
JP7425117B2 (ja) 2024-01-30
JP2024026847A (ja) 2024-02-28
IL259995B1 (en) 2023-01-01
JP7758766B2 (ja) 2025-10-22
CN108602877A (zh) 2018-09-28
US11668718B2 (en) 2023-06-06
JP7092669B2 (ja) 2022-06-28
MX2023000773A (es) 2023-02-22
EP4597115A3 (en) 2025-08-13

Similar Documents

Publication Publication Date Title
AU2022204058B2 (en) Peptide quantitation assay for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK
US20230182139A1 (en) Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
KR20210153097A (ko) 기능성 c1 에스테라제 저해제(fc1-inh)의 정량 방법
JP2025188193A (ja) 完全長の高分子量キニノーゲン(hmwk)と切断されたhmwkとを区別するためのペプチド定量アッセイ
BR112018012165B1 (pt) Método para detectar cininogênio de alto peso molecular (hmwk) clivado, método para diferenciar hmwk completo e hmwk clivado, e método para identificar um sujeito com, ou correndo o risco de ter, angioedema hereditário (hae)
CA2995457C (en) Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
EA040036B1 (ru) Вакуумные пробирки для сбора крови, содержащие ингибиторы протеазы, для оценки активации контактной системы

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211215

EEER Examination request

Effective date: 20211215

EEER Examination request

Effective date: 20211215

EEER Examination request

Effective date: 20211215

EEER Examination request

Effective date: 20211215

EEER Examination request

Effective date: 20211215